Related Experiment Videos
Clinical trials: Evidence and unanswered questions--hyperlipidaemia
1Great Ormond Street Hospital for Children, NHS Trust, Great Ormond Street, London WC1N 3JH, UK. jdeanfield@ich.ucl.ac.uk
Insights
Statin therapy significantly reduces stroke incidence by about one-third in diverse populations. Lowering low-density lipoprotein (LDL) cholesterol with statins offers substantial benefits for cerebrovascular event prevention.
Area of Science:
- Cardiovascular Medicine
- Neurology
- Pharmacology
Background:
- Hypercholesterolemia management is crucial for reducing cardiovascular and cerebrovascular events.
- Statins are a primary pharmacologic intervention for lipid-lowering therapy.
- Cerebrovascular events, such as stroke, represent a significant cause of morbidity and mortality.
Purpose of the Study:
- To summarize the evidence for statin therapy in reducing stroke incidence.
- To highlight the consistent benefits of statins across various patient demographics.
- To discuss the ongoing research evaluating more aggressive lipid-lowering targets for stroke prevention.
Main Methods:
- Review of landmark clinical trials, including the Scandinavian Simvastatin Survival Study and the Heart Protection Study.
- Analysis of data from diverse patient populations, including those with and without diabetes mellitus.
- Consideration of ongoing trials investigating the "lower is better" hypothesis for low-density lipoprotein (LDL) cholesterol.
Main Results:
- Statin therapy consistently reduces stroke incidence by approximately one-third.
- Benefits are observed across different age groups, genders, and in patients with diabetes.
- Stroke risk reduction with statins has been demonstrated even in individuals with initially low LDL cholesterol levels.
Conclusions:
- Statin therapy is a proven strategy for reducing stroke risk.
- Further research is exploring whether even lower LDL cholesterol levels achieved with statins provide additional stroke prevention benefits.
- The SPARCL trial is specifically investigating statin benefits in patients with a history of stroke or TIA but no coronary heart disease.
Abstract:
It is now clear that the management of hypercholesterolaemia is important for the reduction of morbidity and mortality caused by cerebrovascular and coronary events. The landmark Scandinavian Simvastatin Survival Study was the first to show conclusively that lipid-lowering therapy with statins reduces the incidence of stroke. Subsequent trials, undertaken in a variety of different patient populations, have confirmed that statin therapy reduces the incidence of stroke by approximately one-third. This important benefit has been observed in men and women, the young and the elderly, and also in subjects with diabetes mellitus. In the recent Heart Protection Study, which recruited "high-risk" vascular subjects, stroke risk reduction was demonstrated even among those subjects considered to have "low" low-density lipoprotein (LDL) cholesterol levels. The benefits of statin therapy in stroke have been attributed to reductions in cholesterol and to other non-lipid-lowering effects of statins. Ongoing clinical trials such as TNT (Treating to New Targets) and IDEAL (Incremental Decrease in Endpoints through Aggressive Lipid lowering) will test the "lower is better" hypothesis. Using statins to lower LDL cholesterol to levels that are below current guidelines will provide additional benefits in stroke risk reduction. Most of the data on cholesterol reduction and cerebrovascular events have been derived from studies of patients with documented coronary heart disease (CHD). The ongoing SPARCL (Stroke Prevention by Aggressive Reduction in Cholesterol Levels) trial will examine the benefits of LDL cholesterol lowering in patients with previous stroke or transient ischaemic attack (TIA), but no history of coronary problems.